In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund ...

As part of its extensive offerings for the eczema community throughout October, NEA hosts The Ecz-hibition, a social ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

A Insights and GIST Impact to highlight U.S. companies committed to reducing their environmental impact in key areas like ...

According to DelveInsight’s analysis, the growth of the KRAS Inhibitors market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, and robust pipeline ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The man charged with attempting to assassinate Donald Trump after allegedly positioning himself with a rifle outside one of the former president's Florida golf courses on Sept. 15 pleaded not ...

A trader works on the trading floor at The New York Stock Exchange (NYSE), in New York City, U.S., September 18, 2024. REUTERS/Andrew Kelly/File Photo The S&P 500 sputtered to a record high close ...